Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19181299 | 1.00 | KLK7 (0.51) | KLK7KLK5ACECTSLCACNA1B | |
| SCHEMBL18103844 | 0.92 | ACE (0.46) | KLK7KLK5ACE | |
| SCHEMBL19180861 | 0.92 | ACE (0.46) | KLK7KLK5ACE | |
| SCHEMBL18103842 | 0.92 | ACE (0.46) | KLK7KLK5ACE | |
| SCHEMBL19181370 | 0.92 | ACE (0.46) | KLK7KLK5ACE | |
| SCHEMBL18103807 | 0.85 | ACE (0.42) | KLK7KLK5ACECTSL | |
| SCHEMBL18103810 | 0.85 | ACE (0.42) | KLK7KLK5ACECTSL | |
| SCHEMBL19181973 | 0.84 | ACE (0.40) | ACE | |
| SCHEMBL19181972 | 0.84 | ACE (0.40) | ACE | |
| SCHEMBL19181295 | 0.83 | ACE (0.40) | KLK7KLK5ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | KLK7 1326/4885KLK5 719/4885ACE 3216/4885 |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | GZMB, DNASE1L3, DNASE1 | KLK7 1326/4885KLK5 719/4885ACE 3216/4885 |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | KLK7 1326/4885KLK5 719/4885ACE 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.